Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Equivalents (2022 - 2025)

Axsome Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $322.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 2.39% year-over-year to $322.9 million; the TTM value through Dec 2025 reached $322.9 million, up 2.39%, while the annual FY2025 figure was $322.9 million, 2.39% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $322.9 million at Axsome Therapeutics, down from $325.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $437.1 million in Q2 2023 and bottomed at $73.4 million in Q2 2022.
  • The 4-year median for Cash & Equivalents is $315.5 million (2024), against an average of $288.4 million.
  • The largest annual shift saw Cash & Equivalents soared 495.55% in 2023 before it decreased 27.78% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $200.8 million in 2022, then surged by 92.29% to $386.2 million in 2023, then dropped by 18.34% to $315.4 million in 2024, then rose by 2.39% to $322.9 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Cash & Equivalents are $322.9 million (Q4 2025), $325.3 million (Q3 2025), and $303.0 million (Q2 2025).